BMS Bets $8.4bn On Biokin’s Bispecific ADC

New Validation Of Chinese Innovation

 
• By Dexter Jie Yan
  
acquisition deal
BL-B01D1 adds another ADC to BMS's diverse pipeline • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from China

More from Focus On Asia